personnel · US Department of Defense · Rule · Published 2020-06-03 · Effective 2020-07-06 · 85 FR 34101
Document
Document number
2020-10215
Federal Register citation
85 FR 34101
CFR reference
32 CFR 199
Type
Rule
Action
Final rule.
Category
personnel
Sub-agency
US Department of Defense
Publication date
2020-06-03
Effective date
2020-07-06
DOD docket
DOD-2018-HA-0062
Abstract
This rule finalizes Department of Defense (DoD) implementation of Section 702 of the National Defense Authorization Act for Fiscal Year 2018 (NDAA FY18). The law made significant changes to the TRICARE Pharmacy Benefits Program; specifically it: Updated co-payment requirements; authorized a new process for encouraging use of pharmaceutical agents that provide the best clinical effectiveness by excluding coverage for particular pharmaceutical agents that provide very little or no clinical effectiveness relative to similar agents and for giving preferential status to agents that provide enhanced clinical effectiveness; and authorized special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products with respect to pharmaceutical agents provided as part of medical services from authorized providers. This rule finalizes the changes made to the TRICARE Pharmacy Benefit Program as stated in the interim final rule.